Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04450992 · ClinicalTrials.gov registry record
TRACK-MSA: A Longitudinal Study to Define Outcome Measures in Multiple System Atrophy
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 29
- Enrollment target
NCT04450992: Completed study, sponsored by NYU Langone Health.
NCT04450992 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04450992 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 29 participants
- Enrollment target
Study Summary
TRACK-MSA is an observational, non-interventional, longitudinal natural history study to define changes in clinical, neurological, blood, CSF, and neuroimaging biomarkers in patients with multiple system atrophy (MSA) comparing baseline to 6-month and 1-year assessments. The study will enroll 50 patients with MSA-P or MSA-C at 2 or more participating sites.
Primary Outcome
Diffusion-based MRI data
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2020-06-17 |
| Est. Completion | 2024-06-19 |
What the finished NCT04450992 record still lists
NCT04450992 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 29 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04450992 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04450992 about?
NCT04450992 is a clinical study titled "TRACK-MSA: A Longitudinal Study to Define Outcome Measures in Multiple System Atrophy". TRACK-MSA is an observational, non-interventional, longitudinal natural history study to define changes in clinical, neurological, blood, CSF, and neuroimaging biomarkers in patients with multiple system atrophy (MSA) comparing baseline to 6-month and 1-year assessments. The study will enroll 50 pat...
What is the current status of trial NCT04450992?
This trial is currently completed. The enrollment target is 29 participants. The study started on 2020-06-17. Estimated completion is 2024-06-19.
Who is sponsoring clinical trial NCT04450992?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI